Halozyme Therapeutics, Inc. (HALO)
103.63
-19.33
(-15.72%)
USD |
NASDAQ |
Nov 06, 16:00
103.91
+0.28
(+0.27%)
After-Hours: 20:00
Halozyme Therapeutics Total Long Term Debt (Quarterly) : 3.250B for Sept. 30, 2026
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 3.250B |
| June 30, 2026 | 2.147B |
| March 31, 2026 | 2.145B |
| December 31, 2025 | 2.166B |
| September 30, 2025 | 1.511B |
| June 30, 2025 | 1.509B |
| March 31, 2025 | 1.507B |
| December 31, 2024 | 1.529B |
| September 30, 2024 | 1.504B |
| June 30, 2024 | 1.503B |
| March 31, 2024 | 1.501B |
| December 31, 2023 | 1.499B |
| September 30, 2023 | 1.498B |
| June 30, 2023 | 1.496B |
| March 31, 2023 | 1.494B |
| December 31, 2022 | 1.506B |
| September 30, 2022 | 1.504B |
| June 30, 2022 | 1.246B |
| March 31, 2022 | 877.64M |
| December 31, 2021 | 876.67M |
| September 30, 2021 | 875.70M |
| June 30, 2021 | 874.74M |
| March 31, 2021 | 873.77M |
| December 31, 2020 | 397.23M |
| September 30, 2020 | 393.63M |
| Date | Value |
|---|---|
| June 30, 2020 | 390.08M |
| March 31, 2020 | 389.43M |
| December 31, 2019 | 402.59M |
| September 30, 2019 | 63.84M |
| June 30, 2019 | 84.96M |
| March 31, 2019 | 105.40M |
| December 31, 2018 | 126.38M |
| September 30, 2018 | 146.46M |
| June 30, 2018 | 166.04M |
| March 31, 2018 | 185.16M |
| December 31, 2017 | 202.35M |
| September 30, 2017 | 206.85M |
| June 30, 2017 | 211.03M |
| March 31, 2017 | 214.03M |
| December 31, 2016 | 216.62M |
| September 30, 2016 | 212.20M |
| June 30, 2016 | 208.14M |
| March 31, 2016 | 196.02M |
| December 31, 2015 | 49.83M |
| September 30, 2015 | 49.79M |
| June 30, 2015 | 49.75M |
| March 31, 2015 | 49.72M |
| December 31, 2014 | 49.86M |
| September 30, 2014 | 49.84M |
| June 30, 2014 | 49.82M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| AVITA Medical, Inc. | 47.13M |
| Iovance Biotherapeutics, Inc. | 42.77M |
| Merck & Co., Inc. | 49.69B |
| Neurocrine Biosciences, Inc. | 392.30M |
| TG Therapeutics, Inc. | 752.53M |